Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.
V. Tandon, R. M. Vala, A. Chen, R. Sah, H. M. Patel, M. C. Pirrung, S. Banerjee
This study characterizes TIR-199, a proteasome inhibitor that effectively targets myeloma and shows in vivo activity against bone degeneration.
bioRxiv · Oct 27, 2021Biochemistry